Literature DB >> 21232540

Inhibition profile of Leishmania mexicana arginase reveals differences with human arginase I.

Eric Riley1, Sigrid C Roberts, Buddy Ullman.   

Abstract

Arginase (ARG), the enzyme that catalyzes the conversion of arginine to ornithine and urea, is the first and committed step in polyamine biosynthesis in Leishmania. The creation of a conditionally lethal Δarg null mutant in Leishmania mexicana has established that ARG is an essential enzyme for the promastigote form of the parasite and that the enzyme provides an important defense mechanism for parasite survival in the eukaryotic host. Furthermore, human ARGI (HsARGI) has also been implicated as a key factor in parasite proliferation. Thus, inhibitors of ARG offer a rational paradigm for drug design. To initiate a search for inhibitors of the L. mexicana ARG (LmARG), recombinant LmARG and HsARGI enzymes were purified from Escherichia coli. Both LmARG and HsARGI were specific for l-arginine and exhibited no activity with either d-arginine or agmatine as possible substrates. LmARG exhibited a K(m) of 25±4mM for l-arginine, a pH optimum ∼9.0, and was dependent upon the presence of a divalent cation, preferentially manganese. A K(m) of 13.5 ± 2mM for l-arginine was calculated for the HsARGI. A collection of 37 compounds was evaluated against both enzymes. Twelve of these compounds were identified as being either strong inhibitors of both LmARG and HsARGI or differential inhibitors between the two enzymes. Of the 12 compounds, six were selected for further analysis and the type and extent of inhibition determined.
Copyright © 2011 Australian Society for Parasitology Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232540      PMCID: PMC3062745          DOI: 10.1016/j.ijpara.2010.12.006

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  32 in total

1.  Arginase I induction during Leishmania major infection mediates the development of disease.

Authors:  Virginia Iniesta; Jesualdo Carcelén; Isabel Molano; Pablo M V Peixoto; Eloy Redondo; Pilar Parra; Marina Mangas; Isabel Monroy; Maria Luisa Campo; Carlos Gómez Nieto; Inés Corraliza
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo.

Authors:  Pascale Kropf; José M Fuentes; Eva Fähnrich; Luis Arpa; Shanthi Herath; Verena Weber; Germán Soler; Antonio Celada; Manuel Modolell; Ingrid Müller
Journal:  FASEB J       Date:  2005-04-05       Impact factor: 5.191

3.  Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response.

Authors:  Luigi Di Costanzo; Guadalupe Sabio; Alfonso Mora; Paulo C Rodriguez; Augusto C Ochoa; Francisco Centeno; David W Christianson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

4.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells.

Authors:  M Munder; K Eichmann; J M Morán; F Centeno; G Soler; M Modolell
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

5.  Inhibition of human arginase I by substrate and product analogues.

Authors:  Luigi Di Costanzo; Monica Ilies; Katherine J Thorn; David W Christianson
Journal:  Arch Biochem Biophys       Date:  2010-02-12       Impact factor: 4.013

6.  Killing of Leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives.

Authors:  J Mauël; A Ransijn; Y Buchmüller-Rouiller
Journal:  J Leukoc Biol       Date:  1991-01       Impact factor: 4.962

7.  Regulation of arginase isoforms I and II by IL-4 in cultured murine peritoneal macrophages.

Authors:  C A Louis; V Mody; W L Henry; J S Reichner; J E Albina
Journal:  Am J Physiol       Date:  1999-01

8.  Biochemical and biophysical properties of a highly active recombinant arginase from Leishmania (Leishmania) amazonensis and subcellular localization of native enzyme.

Authors:  Edson Roberto da Silva; Maria Fernanda Laranjeira da Silva; Hannes Fischer; Renato A Mortara; Mario Gustavo Mayer; Karine Framesqui; Ariel Mariano Silber; Lucile Maria Floeter-Winter
Journal:  Mol Biochem Parasitol       Date:  2008-03-06       Impact factor: 1.759

9.  Expression, purification, assay, and crystal structure of perdeuterated human arginase I.

Authors:  Luigi Di Costanzo; Martine Moulin; Michael Haertlein; Flora Meilleur; David W Christianson
Journal:  Arch Biochem Biophys       Date:  2007-05-21       Impact factor: 4.013

10.  An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis.

Authors:  Upasna Gaur; Sigrid C Roberts; Rahul P Dalvi; Inés Corraliza; Buddy Ullman; Mary E Wilson
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

View more
  13 in total

1.  Crystal structures of Leishmania mexicana arginase complexed with α,α-disubstituted boronic amino-acid inhibitors.

Authors:  Yang Hai; David W Christianson
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-03-16       Impact factor: 1.056

2.  Differential Regulation of l-Arginine Metabolism through Arginase 1 during Infection with Leishmania mexicana Isolates Obtained from Patients with Localized and Diffuse Cutaneous Leishmaniasis.

Authors:  Arturo A Wilkins-Rodríguez; Armando Pérez-Torres; Alma R Escalona-Montaño; Laila Gutiérrez-Kobeh
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

3.  In vitro antileishmanial activity of fisetin flavonoid via inhibition of glutathione biosynthesis and arginase activity in Leishmania infantum.

Authors:  Keivan Adinehbeigi; Mohammad Hossein Razi Jalali; Ali Shahriari; Somayeh Bahrami
Journal:  Pathog Glob Health       Date:  2017-04-07       Impact factor: 2.894

4.  Crystal structure of arginase from Leishmania mexicana and implications for the inhibition of polyamine biosynthesis in parasitic infections.

Authors:  Edward L D'Antonio; Buddy Ullman; Sigrid C Roberts; Upasna Gaur Dixit; Mary E Wilson; Yang Hai; David W Christianson
Journal:  Arch Biochem Biophys       Date:  2013-04-09       Impact factor: 4.013

5.  Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression.

Authors:  E Yaneth Osorio; Weiguo Zhao; Claudia Espitia; Omar Saldarriaga; Leo Hawel; Craig V Byus; Bruno L Travi; Peter C Melby
Journal:  PLoS Pathog       Date:  2012-01-19       Impact factor: 6.823

6.  Leishmania amazonensis arginase compartmentalization in the glycosome is important for parasite infectivity.

Authors:  Maria Fernanda Laranjeira da Silva; Ricardo Andrade Zampieri; Sandra M Muxel; Stephen M Beverley; Lucile M Floeter-Winter
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

7.  Arginase Is Essential for Survival of Leishmania donovani Promastigotes but Not Intracellular Amastigotes.

Authors:  Jan M Boitz; Caslin A Gilroy; Tamara D Olenyik; Dustin Paradis; Jasmine Perdeh; Kristie Dearman; Madison J Davis; Phillip A Yates; Yuexin Li; Michael K Riscoe; Buddy Ullman; Sigrid C Roberts
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

8.  Inhibition of Leishmania (Leishmania) amazonensis and rat arginases by green tea EGCG, (+)-catechin and (-)-epicatechin: a comparative structural analysis of enzyme-inhibitor interactions.

Authors:  Matheus Balduíno Goncalves dos Reis; Letícia Correa Manjolin; Claudia do Carmo Maquiaveli; Osvaldo Andrade Santos-Filho; Edson Roberto da Silva
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

9.  Crystal structure of Schistosoma mansoni arginase, a potential drug target for the treatment of schistosomiasis.

Authors:  Yang Hai; Jennifer E Edwards; Michael C Van Zandt; Karl F Hoffmann; David W Christianson
Journal:  Biochemistry       Date:  2014-07-09       Impact factor: 3.162

10.  Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei.

Authors:  Isabel M Vincent; Darren J Creek; Karl Burgess; Debra J Woods; Richard J S Burchmore; Michael P Barrett
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.